EDSA NASDAQ
Edesa Biotech, Inc.
1W: -3.7%
1M: -18.9%
3M: -46.5%
YTD: +157.3%
1Y: +50.2%
3Y: -30.2%
5Y: -93.2%
$3.86
-0.15 (-3.74%)
Weekly Expected Move ±12.9%
$3
$3
$4
$4
$5
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$37.2M
52W Range0.72-20.32
Volume18,438
Avg Volume214,966
Beta1.06
Dividend—
Analyst Ratings
Company Info
CEOPardeep Nijhawan
Employees17
SectorHealthcare
IndustryBiotechnology
IPO Date2010-06-21
Websiteedesabiotech.com
100 Spy Court
Markham, ON L3R 5H6
CA
Markham, ON L3R 5H6
CA
289-800-9600
About Edesa Biotech, Inc.
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Nijhawan Pardeep | A-Award | 5,714 | — | 2026-09-01 |
| Nijhawan Pardeep | A-Award | 5,324 | — | 2026-08-03 |
| Nijhawan Pardeep | A-Award | 3,378 | — | 2026-07-02 |
| Nijhawan Pardeep | A-Award | 153,550 | — | 2026-06-16 |
| Nijhawan Pardeep | A-Award | 1,671 | — | 2026-06-01 |